Alnylam (ALNY) Q3 2026 Earnings Call Transcript

Alnylam reported Q3 total revenue of $1.46 billion, up 17% year over year, while net product revenue rose 52% to $1.29 billion, led by TTR franchise revenue of $1.15 billion, up 59%. Management expects full-year TTR product sales of $4.2 billion–$4.5 billion to land at the low end, citing slower-than-anticipated conversion of physician engagement into patient starts and potential Medicare Advantage and 340B-related headwinds; non-GAAP operating income fell 11% to $425 million. The company raised the TRITON-CM enrollment target from 1,750 to 2,250 patients, saying the change addresses potentially lower event rates without altering the expected launch timing of approximately 2030.

Analysis

ALNY’s key near-term issue is conversion, not reach: broader physician engagement has yet to accelerate starts, and management does not expect the field-force expansion to add materially to 2026 sales. The quarter’s U.S. sequential demand gain was partly obscured by inventory and a one-time gross-to-net benefit; with both expected to reverse as reported-growth supports in Q4, the next print is vulnerable to a quality-of-growth downgrade even if underlying prescriptions keep rising. The 340B response is two-sided: alternate sites or WAC purchasing could protect volume and support net price, while deeper discounts or disrupted health-system ordering could pressure both. Until the final rule and provider behavior are observable, 2027 estimates carry unusually wide error bars. UNH’s Medicare Advantage restriction adds a direct friction point for new starts, not evidence of existing-patient churn. Rising Sanofi royalties also mean incremental product revenue does not translate one-for-one into gross profit. Longer term, TRITON-CM’s larger enrollment addresses lower event-rate risk, but does not remove clinical or execution risk; brezosiran’s target engagement is not evidence of clinical benefit. The contrarian risk is treating the large untreated pool and share gains as near-term revenue certainty: prescriber familiarity and access logistics may make conversion slower than category growth implies.

Key Decisions for Investors

• ALNY: avoid chasing the growth headline; consider staged entry only after Q4 results and the February 2027 outlook clarify demand, 340B ordering, and Medicare Advantage impact. Falsify the cautious view if TRX share and underlying starts accelerate without inventory or one-time price support.
• Catalyst watch: track the final CMS 340B rule, health-system purchasing/site-of-care decisions, and ALNY’s gross-to-net and volume disclosures. Treat a material shift to alternate sites/WAC with stable starts as upside; persistent ordering volatility or weaker starts as downside.
• Do not trade the TRITON-CM enrollment increase as a near-term efficacy signal. Reassess on trial updates and later event-rate disclosures; the 2030 opportunity remains conditional on a positive study and approval.
• Monitor ALNY product gross margin alongside TTR sales growth: rising Sanofi royalties can limit operating leverage. No standalone SNY or UNH position is justified by this call alone without quantified earnings exposure.